2.47
+4.22%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sana Biotechnology
From its filings with the US Securities and Exchange Commission
Sana Biotechnology is based in Seattle, Washington and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker SANA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported a net loss of $244.2m. At that date it held total assets of $416.9m and shareholders' equity of $160.9m.
We were founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologic drugs to clinical practice, enabling us to repair cells in the body when possible and replace them when needed. We have developed ex vivo and in vivo cell engineering platforms to revolutionize treatment across a broad array of therapeutic areas with unmet treatment needs, including type 1 diabetes, oncology, and B cell mediated autoimmune diseases.
We are currently focused on advancing two distinct therapeutics, each of which leverages one of these platform technologies. SC451 is our HIP-edited product candidate for the treatment of type 1 diabetes. SG293 is our in vivo CAR T product candidate for the treatment of B cell malignancies and B cell mediated autoimmune diseases.
SC451 is our lead program for T1D. T1D is a disease in which the patient’s immune system attacks and kills the patient’s pancreatic beta cells, the only cells in the human body that make insulin, leading to a complete loss of insulin production in affected individuals. Insulin is essential for normal cellular metabolism, and prior to the discovery of insulin replacement therapy over 100 years ago, a person typically died within months of diagnosis.
Quoted from its 10-K, filed 3 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Feb 2021
- Employees
- 142
- Website
- sana.com ↗
- Head office
- 188 EAST BLAINE STREET, SUITE 350, SEATTLE, WA
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Hans BishopIndependent Chairman of the Board$430,798
- Mr. Steven HarrPresident, Chief Executive Officer, Director, since 2018$8.8m
- Dr. Richard MulliganVice Chairman of the Board, since 2018$363,325
- Ms. Tricia StewartChief People Officer, Executive Vice President
- Mr. Bernard CassidyExecutive Vice President, General Counsel, Company Secretary$2.3m
- Dr. Joshua BilenkerIndependent Director$375,798
- Dr. Douglas ColeIndependent Director$378,298
- Mr. Robert NelsenIndependent Director$370,798
- Dr. Alise ReicinIndependent Director$378,298
- Ms. Michelle SeitzIndependent Director$390,798
- Mr. Patrick YangIndependent Director$375,798
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 20
- Environment
- 19
- Social
- 32
- Governance
- 10
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sana Biotechnology focuses on advanced cell engineering platforms for oncology and genetic disorders.
- Sana's hypoimmune technology enables allogeneic cell therapies for hematologic malignancies.
- Sana's SC291 product candidate targets non-Hodgkin’s lymphoma and leukemia treatments.
Weaknesses
- Sana Biotechnology has 142 employees, which is fewer than industry averages for biotech firms.
- Sana's IPO in 2021 may indicate limited financial resources for expansion.
- Sana's product pipeline includes only three candidates, SC291, SC262, and SC255.
Opportunities
- Sana Biotechnology can expand its cell engineering platforms into cardiovascular diseases and central nervous system disorders.
- Sana's hypoimmune technology could be applied to new therapeutic areas beyond current focus.
- Sana's SC291 and SC262 programs may gain approval for NHL and CLL treatments.
Threats
- Sana Biotechnology faces competition from established biotech firms in the Health Care sector.
- Sana's reliance on a limited number of product candidates creates market vulnerability.
- Sana's IPO in 2021 may lead to increased scrutiny from investors and regulators.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.